Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 281 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... May 25, 2022 To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... February 18, 2021 The power of partnership – the unique alliance taking on brain... December 15, 2022 Bjorn Saven: “By supporting early career researchers to do their jobs... November 19, 2021 Load more HOT NEWS Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... Educators Raise Money in Memory of Teacher Who Dedicated Herself to... How to Strengthen Your Immune System: Part 1 Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up
